文献速递临床试验与 GCP真实世界研究与卫生经济

荷兰立即与延迟序贯双侧白内障手术的安全性、有效性和成本效益(BICAT-NL研究):一项多中心、非劣效性、随机对照试验

Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
PubMed 文献 · Lancet · 2023-05-15

这项多中心非劣效性随机对照试验纳入荷兰十家医院的865例患者,比较立即序贯双侧白内障手术(ISBCS)与延迟序贯双侧白内障手术(DSBCS)。结果显示ISBCS在有效性上非劣于DSBCS,安全性相当,且社会成本更低,成本效益概率为100%。

要点

  • ISBCS组第二眼目标屈光误差≤1.0D的比例为97%,DSBCS组为98%,差异-1%(90%CI -3至1;p=0.526),确立非劣效性。
  • 两组均未观察到或报告眼内炎,不良事件相当,仅 disturbing anisometropia 有显著差异(p=0.0001)。
  • ISBCS的社会成本比DSBCS低403欧元(507美元),在每质量调整生命年2500-80000欧元的支付意愿范围内成本效益概率为100%。

核心结论

  • ISBCS在有效性结局上非劣于DSBCS,安全性相当,且成本效益更优。

研究设计与样本

  • 多中心、非劣效性、随机对照试验,纳入荷兰十家医院的参与者。
  • 纳入标准为18岁及以上、预期手术简单、无眼内炎或屈光意外风险增加。
  • 参与者按1:1随机分配至ISBCS组或DSBCS组,使用网络系统按中心和眼轴长度分层。
  • 参与者和结局评估者因干预性质未设盲。
  • 主要结局为术后4周第二眼目标屈光结局≤1.0屈光度(D)的比例,非劣效性界值为-5%。

主要发现

  • 2018年9月4日至2020年7月10日,共865例患者随机分配至ISBCS组(427例[49%]患者;854眼)或DSBCS组(438例[51%]患者;876眼)。
  • 改良意向性治疗分析中,第二眼目标屈光≤1.0D的比例ISBCS组为97%(404/417例),DSBCS组为98%(407/417例)。
  • 百分比差异为-1%(90%CI -3至1;p=0.526),确立ISBCS相较于DSBCS的非劣效性。
  • 两组均未观察到或报告眼内炎。
  • 不良事件两组相当,仅 disturbing anisometropia 有显著差异(p=0.0001)。

关键数值与推荐

  • 主要结局非劣效性界值为-5%。
  • 第二眼目标屈光结局为≤1.0D。

局限性

  • 参与者和结局评估者因干预性质未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In an ageing population, efficiency improvements are required to assure future accessibility of cataract care. We aim to address remaining knowledge gaps by evaluating the safety, effectiveness, and cost-effectiveness of immediate sequential bilateral cataract surgery (ISBCS) versus delayed sequential bilateral cataract surgery (DSBCS). We hypothesised that ISBCS is non-inferior to DSBCS, regarding safety and effectiveness, and being superior in cost-effectiveness. METHODS: We did a multicentre, non-inferiority, randomised controlled trial, which included participants from ten Dutch hospitals. Eligible participants were 18 years or older, underwent expected uncomplicated surgery, and had no increased risk of endophthalmitis or refractive surprise. Participants were randomly assigned (1:1) to either the ISBCS (intervention) group or DSBCS (conventional procedure) group, using a web-based system stratified by centre and axial length. Participants and outcome assessors were not masked to the treatment groups because of the nature of the intervention. The primary outcome was the proportion of second eyes with a target refractive outcome of 1·0 dioptre (D) or less 4 weeks postoperatively, with a non-inferiority margin of -5% for ISBCS versus DSBCS. For the trial-based economic evaluation, the primary endpoint was the incremental societal costs per quality-adjusted life-year. All analyses were done by a modified intention-to-treat principle. Costs were calculated by multiplying volumes of resource use with unit cost prices and converted to 2020 Euros (€) and US$. This study was registered with ClinicalTrials.gov, number NCT03400124, and is now closed for recruitment. FINDINGS: Between Sept 4, 2018, and July 10, 2020, a total of 865 patients were randomly assigned to either the ISBCS group (427 [49%] patients; 854 eyes) or DSBCS group (438 [51%] patients; 876 eyes). In the modified intention-to-treat analysis, the proportion of second eyes with a target refraction of 1·0 D or less was 97% (404 of 417 patients) in the ISBCS group versus 98% (407 of 417) in the DSBCS group. The percentage difference was -1% (90% CI -3 to 1; p=0·526), thereby establishing non-inferiority for ISBCS compared with DSBCS. Endophthalmitis was not observed or reported in either group. Adverse events were comparable between groups, with only a significant difference in disturbing anisometropia (p=0·0001). Societal costs were €403 (US$507) lower with ISBCS than with DSBCS. The cost-effectiveness probability of ISBCS versus DSBCS was 100% across the willingness-to-pay range of €2500-80 000 (US$3145-100 629) per quality-adjusted life-year. INTERPRETATION: Our results showed non-inferiority of ISBCS versus DSBCS regarding effectiveness outcomes, comparable safety, and superior cost-effectiveness of ISBCS. National cost savings could amount to €27·4 million (US$34·5 million) annually, advocating for ISBCS if strict inclusion criteria are applied. FUNDING: Research grant from The Netherlands Organization for Health Research and Development (ZonMw) and Dutch Ophthalmological Society.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Spekreijse L, Simons R, Winkens B, et al. Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial. Lancet. 2023. PMID: 37201546. doi:10.1016/S0140-6736(23)00525-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。